Exscientia Plc

Hello, everyone. My name is Brent, and I will be your conference operator today. At this time, I would like to welcome everyone to Accenture's business update call for the third quarter of 2022. All lines have been placed on mute to prevent any background noise. After the speech remarks, there will be a question and answer session. If you would like to ask a question at that time, simply press star, followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press star one. Thank you. At this time, I'd like to introduce Sarah Sherman, Vice President of Investor Relations.

Sarah, you may begin.

Thank you, Operator. A press release and 6K were issued this morning with our third quarter 2022 financial results and business update. These documents can be found on our website at www.investors.excentria.ai. along with a presentation for today's webcast. Before we begin, I'd like to remind you that we may make forward-looking statements on our call. These may include statements about our projected growth, revenue, business models, preclinical and clinical results, and business performance. Actual results may differ materially from those indicated by these statements. Unless required by law, Accenture does not undertake any obligation to update these statements regarding the future or to confirm these statements in relation to actual results. On today's call, I'm joined by Andrew Hopkins, Chief Executive Officer, and Ben Taylor, CFO and Chief Strategy Officer. Dave Hallett, Chief Operating Officer, Mike Krems, Chief Quantitative Medicine Officer, and Gary Paradue, Chief Technology Officer, will also be available for the Q&A session. And with that, I will now turn the call over to Andrew.